Ovarian cancer incidence is also strongly related to age, with the highest incidence rates being in elderly women. According to a European cancer observatory, EUCAN, incidence accounted in 2012 for 44.149 women in the EU. 42.704 deaths were recorded in Europe that year due to this both highly prevalent and deadly disease. Carcinoma of the ovary therapy is an unmet and prevalent medical need affecting females. Improvement is needed both in terms of early diagnosis and treatment. At advanced stages following surgery and chemotherapy based on platinum and taxanes, both quality and expectancy of life is currently poor. We plan to impact the prognosis of this population of female patients with a novel immunotherapy delaying or preventing post-surgical relapse in cases in which there is NED left after secondary surgery, but in which almost 100% of patients relapse following the procedure despite adjuvant therapy with platinum compounds, Gemcitabine with or without Bevacizumab. Adding therapeutic vaccines at this stage of minimal residual disease holds promise to prolong disease-free survival and would be a valuable therapeutic tool for physicians with the aim of extending survival with good quality of life. By clinical trial design, the specified number of patients will permit statistical evidence for benefit comparing the outcome of the secondary cytoreductive surgery with the first debulking surgery. This clinical trial design aspect is highly innovative and will accomplish the attainment of conclusive information with a limited series of well selected patients.
Prostate cancer is a serious non-communicable disease of elderly males that creates a huge health problem in aging Europe. According to EUCAN, 416.732 European citizens were diagnosed of prostate cancer in 2012 and this accounts for an average incidence rate of 92 cases per 100.000 inhabitants in the European age-standardized population. The disease was mortal in over 92.237 men in Europe that year, with at least 71.023 deaths occurring within the EU boundaries. Prostate cancer is therefore the second leading cause of cancer death in European men, only after lung cancer, and a serious health issue in elderly citizens. If the disease is diagnosed at a localized stage (I and II) options of treatment include radiotherapy, if possible applied with brachytherapy, and surgery. Radical retropubic prostatectomy is the usual operation of choice in cases in which tumour diameter is large and differentiation of tissue is poor according to Gleason score. As this disease mainly affects the elderly population this will be an increasingly more serious problem in aging Europe, with the highest prevalence and mortality observed in the most aged populations of the continent. Advanced stages are treated with androgen suppression, chemotherapy and novel antiandrogen receptor compounds. Although there is fast progress in the management of the advanced disease, once it becomes hormone resistant, life expectancy and quality of life are rather poor in spite of chemotherapy treatment. Innovative, cost-effective therapeutic approaches are required to provide the best quality of care at this stage in which prevention of relapse would be most meaningful for both the life-expectancy and quality of life of about one third of the operated patients.